Chemomab Therapeutics Ltd DRC logo

Chemomab Therapeutics Ltd DRC(CMMB)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.55
11/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CMMB

11/18/2026: CMMB (1-star) is currently NOT-A-BUY. Pass it for now.

Chemomab Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody treatments for fibrotic and inflammatory diseases. Its primary asset, nebokitug, targets the CCL24 protein pathway and has advanced through mid-stage clinical trials for conditions like primary sclerosing cholangitis. The primary investment appeal lies in the potential of its first-in-class pipeline and strategic merger initiatives designed to address severe unmet medical needs. However, the enterprise faces substantial risks, including pre-revenue financial losses, heavy asset concentration, and clinical trial uncertainty. The stock suits risk-tolerant investors seeking biotechnology exposure, with key developments resting on upcoming clinical readouts and regulatory milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers high-growth pipeline potential if clinical milestones are met, but lacks current commercial revenue.
Momentum investorStrong fit while signal remains positiveCan experience sharp price movements and surges around clinical data readouts and corporate merger catalysts.
Value investorWeak fitTraditional value metrics like P/E ratios and cash flows do not apply to pre-revenue clinical biotechnology firms.
Dividend investorWeak fitThe company pays zero dividends, rendering it unsuitable for income-focused portfolios.
Low-risk investorWeak fitHigh clinical trial risks and stock price volatility make it inappropriate for conservative capital preservation.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences significant price swings driven by clinical trial updates, regulatory news, and biotech market sentiment.
Valuation riskHighValuation relies entirely on speculative clinical potential rather than fundamental earnings or sales streams.
Competition risk (fibrosis and immunology drug developers)Medium / highWell-funded pharmaceutical competitors are constantly pursuing alternative treatments for fibro-inflammatory conditions.
Business qualityMediumWhile scientifically innovative with a first-in-class target, the enterprise remains early-stage and pre-commercial.
Dividend incomeLow / noneNo dividend distributions are paid or anticipated as all funds are channeled into R&D.
Execution riskHighSuccess depends heavily on executing complex clinical trials and securing favorable regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 13.20M USD
Price to earnings Ratio -
1Y Target Price 5
Price to earnings Ratio -
1Y Target Price 5
Volume (30-day avg) 55.5K shares
Beta 0.79
52 Weeks Range 0.92 - 2.99
Updated Date 11/18/2026
52 Weeks Range 0.92 - 2.99
Updated Date 11/18/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.04

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.0%
Active BUY / eligible
67 / 108
30-Day BUY Count Change
+22
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
43.6%
Active BUY / eligible
17 / 39
30-Day BUY Count Change
+10

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -48.42%
Avg. Invested days 17
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/18/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CMMB receives a 3-star rating based on the available scored pillars. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
CMMB has moderate overall fundamentals (3 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+35.5%) is partially offset by soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
CMMB's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is CMMB's strongest growth driver at +35.5% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+27.4%, solid) is also solid, while revenue growth (+0.0%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 20.0% and approximately 62.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 6.57% supports management-shareholder alignment.

Top 5 Institutional Investors

Advisory Services Network, LLC 0.00%

Unit Economics (Per $1K Revenue)

★★★★★
CMMB generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
CMMB has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Development & LicensingPotential future commercial product sales, out-licensing fees, and milestone payments associated with nebokitug.The company currently makes no money from product sales and operates as a clinical-stage research enterprise.

Valuation

Trailing PE -
Forward PE 12.94
Enterprise Value 2.91M
Price to Sales(TTM) -
Enterprise Value 2.91M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.33
Shares Outstanding 8.05M
Shares Floating 5.05M
Shares Outstanding 8.05M
Shares Floating 5.05M
Percent Insiders 6.57
Percent Institutions 20.04

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.